Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.

abstract：OBJECTIVE:The aim of this study was to evaluate medication adherence and persistence of patients treated with Etanercept and Adalimumab for Rheumatoid Arthritis, also giving economic evaluations on therapy costs for Received Daily Dose (RDD). MATERIALS AND METHODS:This retrospective study took into account 6 years fro...

journal_title：Journal of medical economics

authors： Santoleri F,Sorice P,Lasala R,Rizzo RC,Costantini A

更新日期：2014-05-01 00:00:00

abstract：OBJECTIVE:A new and smaller percutaneous ventricular assist device (pVAD, Impella, Abiomed, Danvers, MA) has been developed to provide circulatory support in hemodynamically unstable patients and to prevent hemodynamic collapse during high-risk percutaneous coronary interventions (PCI). The objective of the study was t...

journal_title：Journal of medical economics

authors： Roos JB,Doshi SN,Konorza T,Palacios I,Schreiber T,Borisenko OV,Henriques JP

更新日期：2013-01-01 00:00:00

abstract：:Aims: Estimate the direct costs of high-risk patients presenting with coronary artery disease (CAD) or peripheral artery disease (PAD) in France.Materials and methods: This retrospective cohort study used a representative claims database, the "Echantillon Généraliste de Bénéficiaires" (EGB), to identify patients prese...

journal_title：Journal of medical economics

authors： Emery C,Torreton E,Briere JB,Evers T,Fagnani F

更新日期：2020-05-01 00:00:00

abstract：OBJECTIVE:The past few decades have been marked by a bold increase in national health spending across the globe. Rather successful health reforms in leading emerging markets such as BRICS reveal a reshaping of their medical care-related expenditures. There is a scarcity of evidence explaining differences in long-term m...

journal_title：Journal of medical economics

authors： Jakovljevic MM

更新日期：2016-01-01 00:00:00

abstract：:Aims: To evaluate total costs and health consequences of a colorectal cancer (CRC) screening program with colonoscopy, fecal immunochemical tests (FIT), and expanded use of multitarget stool DNA (mt-sDNA) from the perspectives of Integrated Delivery Networks (IDNs) and payers in the United States.Materials and methods...

journal_title：Journal of medical economics

authors： Hathway JM,Miller-Wilson LA,Jensen IS,Ozbay B,Regan C,Jena AB,Weinstein MC,Parks PD

更新日期：2020-06-01 00:00:00

abstract：OBJECTIVE:Compare long-term costs and outcomes of lurasidone to aripiprazole among adults with schizophrenia in the US who previously failed ≥1 atypical antipsychotic (olanzapine, risperidone, quetiapine, or ziprasidone) based on an indirect comparison of outcomes data from clinical trials. METHODS:A 5-year Markov coh...

journal_title：Journal of medical economics

authors： Rajagopalan K,Hassan M,O'Day K,Meyer K,Grossman F

更新日期：2013-07-01 00:00:00

abstract：OBJECTIVE:In the phase III SECURE trial, isavuconazole was non-inferior to voriconazole for all-cause mortality for the primary treatment of invasive mold disease (IMD) caused by Aspergillus spp. and other filamentous fungi. This analysis assessed whether hospital resource utilization was different between patients tre...

journal_title：Journal of medical economics

authors： Horn D,Goff D,Khandelwal N,Spalding J,Azie N,Shi F,Franks B,Shorr AF

更新日期：2016-07-01 00:00:00

abstract：OBJECTIVE:To review, summarize, and analyze both similarities and differences of pharmacoeconomic (PE) guidelines, to enable researchers to access their characteristics and the current state of PE guidelines; furthermore, to learn which methodological issues still remain contested and to promote the methodological deve...

journal_title：Journal of medical economics

authors： Zhao Y,Feng HM,Qu J,Luo X,Ma WJ,Tian JH

更新日期：2018-01-01 00:00:00

abstract：OBJECTIVE:This analysis was conducted to compare the direct medical costs of treatment with darbepoetin alfa every 3 weeks (Q3W) and epoetin alfa every week (QW) in patients with chemotherapy-induced anaemia (CIA) from the payer's perspective. METHODS:An analysis was conducted from a US health plan perspective to comp...

journal_title：Journal of medical economics

authors： Rubin RJ,Glaspy JA,Adams JL,Mafilios MS,Wang SM,Viswanathan HN,Kallich JD

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Biologic treatments have enhanced the treatment outcomes of patients with active ankylosing spondylitis (AS). Until recently, TNF-alpha-inhibitors have been the only biologics approved for the treatment of active AS. The objective of this study was to assess the potential financial impact of the first non-TN...

journal_title：Journal of medical economics

authors： Purmonen T,Törmälehto S,Wahlman H,Puolakka K

更新日期：2019-02-01 00:00:00

abstract：AIMS:To compare patient characteristics, rates, and costs of medically attended falls among patients with Parkinson's disease (PD) and probable PD plus neurogenic orthostatic hypotension (PD + nOH). MATERIALS AND METHODS:MarketScan Commercial and Medicare Supplemental databases (January 1, 2009-December 31, 2013) were...

journal_title：Journal of medical economics

authors： François C,Biaggioni I,Shibao C,Ogbonnaya A,Shih HC,Farrelly E,Ziemann A,Duhig A

更新日期：2017-05-01 00:00:00

abstract：OBJECTIVE:To estimate the economic implications of introducing dabigatran etexilate ('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial fibrillation based on results of the RE-LY trial. METHODS:The lifetime cost and outcomes of dabigatran and warfarin were estimated using a previous...

journal_title：Journal of medical economics

authors： Langkilde LK,Bergholdt Asmussen M,Overgaard M

更新日期：2012-01-01 00:00:00

abstract：OBJECTIVES:Non-severe nocturnal hypoglycemic events (NSNHEs) may have a major impact on patients. The objective was to determine how NSNHEs affect diabetes management, sleep quality, functioning, and to assess if these impacts differ by diabetes type or country. METHODS:An internet survey to adults with diabetes in th...

journal_title：Journal of medical economics

authors： Brod M,Christensen T,Bushnell DM

更新日期：2012-01-01 00:00:00

abstract：:Aims: Nocturia (getting up at night to urinate, where each urination being followed by sleep or intention to sleep) is a bothersome symptom with potentially negative consequences for individual health and daytime functioning. This study assessed the burden of nocturia in the workplace by investigating associations bet...

journal_title：Journal of medical economics

authors： Hafner M,Andersson FL,Burtea T,van Stolk C,Whitmore M,Yerushalmi E,Troxel WM

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:Growing financial pressure on US dialysis providers requires economic efficiency considerations. The objective of this study was to examine short-term economic efficiencies of a cinacalcet-based treatment approach for secondary hyperparathyroidism. METHODS:This study retrospectively assessed cost per bioche...

journal_title：Journal of medical economics

authors： Belozeroff V,Lee A,Tseng S,Chiroli S,Campbell JD

更新日期：2013-09-01 00:00:00

abstract：OBJECTIVE:The only effective treatment for severe aortic stenosis (AS) is valve replacement. However, many patients with co-existing conditions are ineligible for surgical valve replacement, historically leaving medical management (MM) as the only option which has a poor prognosis. Transcatheter Aortic Valve Replacemen...

journal_title：Journal of medical economics

authors： Hancock-Howard RL,Feindel CM,Rodes-Cabau J,Webb JG,Thompson AK,Banz K

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVE:To estimate the annualized differences in direct medical and indirect costs associated with improvement in fibromyalgia (FM) severity among pregabalin-treated patients. METHODS:Data from three clinical trials of pregabalin in patients with FM were modeled; efficacy results were extrapolated. Mean annual cost...

journal_title：Journal of medical economics

authors： Cappelleri JC,Bushmakin AG,Zlateva G,Chandran A

更新日期：2013-01-01 00:00:00

abstract：AIMS:In this pharmacoeconomic simulation, we: (1) modeled the cost-efficiency of converting patients from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv for prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) from the US payer perspective, (2) simulated how savings enable, on a budget-neutral b...

journal_title：Journal of medical economics

authors： MacDonald K,McBride A,Alrawashdh N,Abraham I

更新日期：2020-10-24 00:00:00

abstract：OBJECTIVE:This study evaluated infection-related hospitalization risk and cost in tumor necrosis factor inhibitor (TNFi)-experienced and targeted DMARD (tDMARD) naïve rheumatoid arthritis (RA) patients that were treated with abatacept, TNFi, or other non-TNFi. METHODS:This retrospective study used 100% Medicare Fee-fo...

journal_title：Journal of medical economics

authors： Patel V,Pulungan Z,Shah A,Kambhampati M,Lobo F,Petrilla A

更新日期：2021-01-27 00:00:00

abstract：AIMS:This paper evaluates the impact of multiple sclerosis (MS) in Ireland, and estimates the associated direct, indirect, and intangible costs to society based on a large nationally representative sample. MATERIALS AND METHODS:A questionnaire was developed to capture the demographics, disease characteristics, healthc...

journal_title：Journal of medical economics

authors： Carney P,O'Boyle D,Larkin A,McGuigan C,O'Rourke K

更新日期：2018-05-01 00:00:00

abstract：OBJECTIVES:Two anti-cancer drugs are currently approved for the treatment of HER2-positive metastatic breast cancer (MBC): trastuzumab-based therapy (TBT) administered intravenously as first line therapy until disease progression and lapatinib, an oral self-administered dual therapy with capecitabine (L+C) as second in...

journal_title：Journal of medical economics

authors： Benjamin L,Buthion V,Iskedjian M,Farah B,Rioufol C,Vidal-Trécan G

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Systemic Candida infections (SCI) occur predominantly in intensive care unit patients and are a common cause of morbidity and mortality. Recently, changes in Candida epidemiology with an increasing prevalence of SCI caused by Candida non-albicans species have been reported. Resistance to fluconazole and azol...

journal_title：Journal of medical economics

authors： Masterton RG,Casamayor M,Musingarimi P,van Engen A,Zinck R,Odufowora-Sita O,Odeyemi IA

更新日期：2013-11-01 00:00:00

abstract：AIM:This analysis assessed the direct medical costs of newly-diagnosed, temozolomide (TMZ)-treated glioblastoma (GBM) from the perspective of a US commercial setting. MATERIALS AND METHODS:The analysis included subjects identified from the IMS PharMetrics LifeLink Plus™ claims database from January 1, 2008 to August 3...

journal_title：Journal of medical economics

authors： Jiang S,Hill K,Patel D,Waldeck AR,Botteman M,Aly A,Norden AD

更新日期：2017-12-01 00:00:00

abstract：OBJECTIVE:To assess patient characteristics, treatment patterns, and healthcare resource utilization (HRU)/costs of individuals treated for neuroendocrine tumors (NETs) in the US. METHODS:Using a US administrative claims database, this study identified commercially-insured adults newly diagnosed with carcinoid tumors ...

journal_title：Journal of medical economics

authors： Chuang CC,Bhurke S,Chen SY,Brulais S,Gabriel S

更新日期：2015-02-01 00:00:00

abstract：OBJECTIVES:To describe the changes in resource utilization in seven European countries (Germany, Greece, Portugal, Romania, Sweden, Spain, and Turkey) and direct costs in four European countries (Germany, Spain, Sweden, and Greece) over the first 12 months of insulin treatment in patients with type 2 diabetes mellitus ...

journal_title：Journal of medical economics

authors： Brismar K,Benroubi M,Nicolay C,Schmitt H,Giaconia J,Reaney M

更新日期：2013-08-01 00:00:00

abstract：OBJECTIVES:This study examines the epidemiology and economic impact of chronic obstructive pulmonary disease (COPD) at a nationwide level in South Korea. METHODS:This retrospective analysis used the societal cost-of-illness framework, consisting of direct medical costs, direct non-medical costs, and indirect costs. In...

journal_title：Journal of medical economics

authors： Kim J,Lee TJ,Kim S,Lee E

更新日期：2016-01-01 00:00:00

abstract：OBJECTIVE:Systemic lupus erythematosus is a complex autoimmune disease, most frequently affecting women of childbearing age. Women with lupus are at increased risk of pregnancy complications that are exacerbated by active disease. Despite this, their use of medications and hospital resources has not been extensively st...

journal_title：Journal of medical economics

authors： Petri M,Daly RP,Pushparajah DS

更新日期：2015-01-01 00:00:00

abstract：:Aims: OnabotulinumtoxinA is recommended by NICE for the treatment of chronic migraine. This economic evaluation provides updated estimates of the cost-effectiveness of onabotulinumtoxinA for chronic migraine using new utility estimates in an existing model structure.Methods: A previously published model was revised to...

journal_title：Journal of medical economics

authors： Hollier-Hann G,Curry A,Onishchenko K,Akehurst R,Ahmed F,Davies B,Keyzor I

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:In the last decade, the number of new agents, including monoclonal antibodies, being developed to treat metastatic colorectal cancer (mCRC) increased rapidly. While improving outcomes, these new treatments also have distinct and known safety profiles with toxicities that may require hospitalizations. However...

journal_title：Journal of medical economics

authors： Overbeek JA,Zhao Z,van Herk-Sukel MP,Barber BL,Gao S,Herings RM

更新日期：2011-01-01 00:00:00

abstract：:Aims: To evaluate costs in patients with diabetes who experienced a macrovascular complication from a Brazilian public healthcare system perspective.Materials and methods: A retrospective, observational study that utilized the database of the Brazilian Unified Health System (DATASUS). Data for direct medical costs (ho...

journal_title：Journal of medical economics

authors： Julian GS,Campos D,Broe Honore J,Sauer Tobaruella F,Hyun Yoon J,Hallén N

更新日期：2020-09-01 00:00:00